198 related articles for article (PubMed ID: 20460644)
1. Phase I clinical and pharmacokinetic study of a novel schedule of flavopiridol in relapsed or refractory acute leukemias.
Blum W; Phelps MA; Klisovic RB; Rozewski DM; Ni W; Albanese KA; Rovin B; Kefauver C; Devine SM; Lucas DM; Johnson A; Schaaf LJ; Byrd JC; Marcucci G; Grever MR
Haematologica; 2010 Jul; 95(7):1098-105. PubMed ID: 20460644
[TBL] [Abstract][Full Text] [Related]
2. Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias.
Karp JE; Smith BD; Resar LS; Greer JM; Blackford A; Zhao M; Moton-Nelson D; Alino K; Levis MJ; Gore SD; Joseph B; Carraway H; McDevitt MA; Bagain L; Mackey K; Briel J; Doyle LA; Wright JJ; Rudek MA
Blood; 2011 Mar; 117(12):3302-10. PubMed ID: 21239698
[TBL] [Abstract][Full Text] [Related]
3. Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias.
Karp JE; Passaniti A; Gojo I; Kaufmann S; Bible K; Garimella TS; Greer J; Briel J; Smith BD; Gore SD; Tidwell ML; Ross DD; Wright JJ; Colevas AD; Bauer KS
Clin Cancer Res; 2005 Dec; 11(23):8403-12. PubMed ID: 16322302
[TBL] [Abstract][Full Text] [Related]
4. Exposure-Response Analysis of Alvocidib (Flavopiridol) Treatment by Bolus or Hybrid Administration in Newly Diagnosed or Relapsed/Refractory Acute Leukemia Patients.
LaCerte C; Ivaturi V; Gobburu J; Greer JM; Doyle LA; Wright JJ; Karp JE; Rudek MA
Clin Cancer Res; 2017 Jul; 23(14):3592-3600. PubMed ID: 28174232
[No Abstract] [Full Text] [Related]
5. Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia.
Byrd JC; Lin TS; Dalton JT; Wu D; Phelps MA; Fischer B; Moran M; Blum KA; Rovin B; Brooker-McEldowney M; Broering S; Schaaf LJ; Johnson AJ; Lucas DM; Heerema NA; Lozanski G; Young DC; Suarez JR; Colevas AD; Grever MR
Blood; 2007 Jan; 109(2):399-404. PubMed ID: 17003373
[TBL] [Abstract][Full Text] [Related]
6. Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: results from Cancer and Leukemia Group B study 19805.
Byrd JC; Peterson BL; Gabrilove J; Odenike OM; Grever MR; Rai K; Larson RA;
Clin Cancer Res; 2005 Jun; 11(11):4176-81. PubMed ID: 15930354
[TBL] [Abstract][Full Text] [Related]
7. Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms.
Tan AR; Headlee D; Messmann R; Sausville EA; Arbuck SG; Murgo AJ; Melillo G; Zhai S; Figg WD; Swain SM; Senderowicz AM
J Clin Oncol; 2002 Oct; 20(19):4074-82. PubMed ID: 12351605
[TBL] [Abstract][Full Text] [Related]
8. A dose-finding, pharmacokinetic and pharmacodynamic study of a novel schedule of flavopiridol in patients with advanced solid tumors.
Ramaswamy B; Phelps MA; Baiocchi R; Bekaii-Saab T; Ni W; Lai JP; Wolfson A; Lustberg ME; Wei L; Wilkins D; Campbell A; Arbogast D; Doyle A; Byrd JC; Grever MR; Shah MH
Invest New Drugs; 2012 Apr; 30(2):629-38. PubMed ID: 20938713
[TBL] [Abstract][Full Text] [Related]
9. Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia.
Phelps MA; Lin TS; Johnson AJ; Hurh E; Rozewski DM; Farley KL; Wu D; Blum KA; Fischer B; Mitchell SM; Moran ME; Brooker-McEldowney M; Heerema NA; Jarjoura D; Schaaf LJ; Byrd JC; Grever MR; Dalton JT
Blood; 2009 Mar; 113(12):2637-45. PubMed ID: 18981292
[TBL] [Abstract][Full Text] [Related]
10. Reduced occurrence of tumor flare with flavopiridol followed by combined flavopiridol and lenalidomide in patients with relapsed chronic lymphocytic leukemia (CLL).
Maddocks K; Wei L; Rozewski D; Jiang Y; Zhao Y; Adusumilli M; Pierceall WE; Doykin C; Cardone MH; Jones JA; Flynn J; Andritsos LA; Grever MR; Byrd JC; Johnson AJ; Phelps MA; Blum KA
Am J Hematol; 2015 Apr; 90(4):327-33. PubMed ID: 25639448
[TBL] [Abstract][Full Text] [Related]
11. Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a phase II trial in adults with poor-risk acute myelogenous leukemia.
Karp JE; Smith BD; Levis MJ; Gore SD; Greer J; Hattenburg C; Briel J; Jones RJ; Wright JJ; Colevas AD
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4467-73. PubMed ID: 17671131
[TBL] [Abstract][Full Text] [Related]
12. Flavopiridol in the treatment of chronic lymphocytic leukemia.
Christian BA; Grever MR; Byrd JC; Lin TS
Curr Opin Oncol; 2007 Nov; 19(6):573-8. PubMed ID: 17906454
[TBL] [Abstract][Full Text] [Related]
13. Flavopiridol administered as a 24-hour continuous infusion in chronic lymphocytic leukemia lacks clinical activity.
Flinn IW; Byrd JC; Bartlett N; Kipps T; Gribben J; Thomas D; Larson RA; Rai K; Petric R; Ramon-Suerez J; Gabrilove J; Grever MR
Leuk Res; 2005 Nov; 29(11):1253-7. PubMed ID: 15916806
[TBL] [Abstract][Full Text] [Related]
14. Clinical pharmacology of flavopiridol following a 72-hour continuous infusion.
Rudek MA; Bauer KS; Lush RM; Stinson SF; Senderowicz AM; Headlee DJ; Arbuck SG; Cox MC; Murgo AJ; Sausville EA; Figg WD
Ann Pharmacother; 2003 Oct; 37(10):1369-74. PubMed ID: 14519054
[TBL] [Abstract][Full Text] [Related]
15. Phase I clinical and pharmacokinetic study of flavopiridol in children with refractory solid tumors: a Children's Oncology Group Study.
Whitlock JA; Krailo M; Reid JM; Ruben SL; Ames MM; Owen W; Reaman G;
J Clin Oncol; 2005 Dec; 23(36):9179-86. PubMed ID: 16361620
[TBL] [Abstract][Full Text] [Related]
16. A phase I trial of vorinostat and alvocidib in patients with relapsed, refractory, or poor prognosis acute leukemia, or refractory anemia with excess blasts-2.
Holkova B; Supko JG; Ames MM; Reid JM; Shapiro GI; Perkins EB; Ramakrishnan V; Tombes MB; Honeycutt C; McGovern RM; Kmieciak M; Shrader E; Wellons MD; Sankala H; Doyle A; Wright J; Roberts JD; Grant S
Clin Cancer Res; 2013 Apr; 19(7):1873-83. PubMed ID: 23515411
[TBL] [Abstract][Full Text] [Related]
17. Phase 1/2 study of DFP-10917 administered by continuous intravenous infusion in patients with recurrent or refractory acute myeloid leukemia.
Kantarjian HM; Jabbour EJ; Garcia-Manero G; Kadia TM; DiNardo CD; Daver NG; Borthakur G; Jain N; Waukau JB; Kwari MI; Ravandi F; Anderson BD; Iizuka K; Jin C; Zhang C; Plunkett WK
Cancer; 2019 May; 125(10):1665-1673. PubMed ID: 30668890
[TBL] [Abstract][Full Text] [Related]
18. Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol.
Thomas JP; Tutsch KD; Cleary JF; Bailey HH; Arzoomanian R; Alberti D; Simon K; Feierabend C; Binger K; Marnocha R; Dresen A; Wilding G
Cancer Chemother Pharmacol; 2002 Dec; 50(6):465-72. PubMed ID: 12451473
[TBL] [Abstract][Full Text] [Related]
19. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms.
Senderowicz AM; Headlee D; Stinson SF; Lush RM; Kalil N; Villalba L; Hill K; Steinberg SM; Figg WD; Tompkins A; Arbuck SG; Sausville EA
J Clin Oncol; 1998 Sep; 16(9):2986-99. PubMed ID: 9738567
[TBL] [Abstract][Full Text] [Related]
20. Phase I trial of bortezomib (PS-341; NSC 681239) and "nonhybrid" (bolus) infusion schedule of alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory indolent B-cell neoplasms.
Holkova B; Kmieciak M; Perkins EB; Bose P; Baz RC; Roodman GD; Stuart RK; Ramakrishnan V; Wan W; Peer CJ; Dawson J; Kang L; Honeycutt C; Tombes MB; Shrader E; Weir-Wiggins C; Wellons M; Sankala H; Hogan KT; Colevas AD; Doyle LA; Figg WD; Coppola D; Roberts JD; Sullivan D; Grant S
Clin Cancer Res; 2014 Nov; 20(22):5652-62. PubMed ID: 25248382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
